The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions

Onozawa, 2014, Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan, Jpn J Clin Oncol, 44, 969, 10.1093/jjco/hyu104 Tanaka, 2017, Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012, BMC Cancer, 17, 616, 10.1186/s12885-017-3637-2 Tanaka, 2013, Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009, BMC Cancer, 13, 588, 10.1186/1471-2407-13-588 Tanaka, 2011, Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study, Int J Clin Oncol, 16, 553, 10.1007/s10147-011-0226-2 Han, 2001, Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience, Urol Clin North Am, 28, 555, 10.1016/S0094-0143(05)70163-4 Trock, 2008, Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy, JAMA, 299, 2760, 10.1001/jama.299.23.2760 Katz, 2003, Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer, J Clin Oncol, 21, 483, 10.1200/JCO.2003.12.043 Stephenson, 2007, Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy, J Clin Oncol, 25, 2035, 10.1200/JCO.2006.08.9607 Miyake, 2014, Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study, Radiat Oncol, 9, 208, 10.1186/1748-717X-9-208 Pilepich, 1997, Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31, J Clin Oncol, 15, 1013, 10.1200/JCO.1997.15.3.1013 Hanks, 2003, Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02, J Clin Oncol, 21, 3972, 10.1200/JCO.2003.11.023 Zapatero, 2015, High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial, Lancet Oncol, 16, 320, 10.1016/S1470-2045(15)70045-8 Shipley, 2017, Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer, N Engl J Med, 376, 417, 10.1056/NEJMoa1607529 Carrie, 2016, Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial, Lancet Oncol, 17, 747, 10.1016/S1470-2045(16)00111-X Nielsen, 2007, The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer, Rev Urol, 9, 57 Cookson, 2007, J Urol, 177, 540 Sia, 2008, Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting, Can Urol Assoc J, 2, 500, 10.5489/cuaj.916 Higano, 2003, Side effects of androgen deprivation therapy: monitoring and minimizing toxicity, Urology, 61, 32, 10.1016/S0090-4295(02)02397-X Torimoto, 2011, The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer, Jpn J Clin Oncol, 41, 577, 10.1093/jjco/hyr005 Cherullo, 2002, Variable definitions influence the reporting of biochemical failure rates, Prostate Cancer Prostatic Dis, 5, 54, 10.1038/sj.pcan.4500545 Thames, 2003, Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995, Int J Radiat Oncol Biol Phys, 57, 929, 10.1016/S0360-3016(03)00631-X Williams, 2006, Characterization of the behavior of three definitions of prostate-specific antigen-based biochemical failure in relation to detection and follow-up biases: comparison with the American Society for Therapeutic Radiology and Oncology consensus definition, Int J Radiat Oncol Biol Phys, 64, 849, 10.1016/j.ijrobp.2005.08.003 American Society for Therapeutic Radiology and Oncology Consensus Panel, 1997, Consensus statement: guidelines for PSA following radiation therapy, Int J Radiat Oncol Biol Phys, 37, 1035 Kuban, 2005, Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?, Int J Radiat Oncol Biol Phys, 61, 409, 10.1016/j.ijrobp.2004.05.021 Roach, 2006, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol Biol Phys, 65, 965, 10.1016/j.ijrobp.2006.04.029